VIATRIS INC. Restructuring Charges
VIATRIS INC. (VTRS) reported Restructuring Charges of $27.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-08-06
- VIATRIS INC. restructuring charges for the quarter ending 2026-06-30 was $27.30M.
- VIATRIS INC. restructuring charges for the quarter ending 2026-03-31 was $77.90M.
- VIATRIS INC. restructuring charges for the quarter ending 2023-09-30 was $14.90M, a 0.00% change year-over-year.
- VIATRIS INC. restructuring charges for the quarter ending 2023-06-30 was $74.00M, a 655.10% increase year-over-year.
- VIATRIS INC. restructuring charges for fiscal 2021 was $50.50M, a 0.00% change from fiscal 2020.
- VIATRIS INC. restructuring charges for fiscal 2020 was $50.50M, a 51.72% decline from fiscal 2019.
- VIATRIS INC. restructuring charges for fiscal 2019 was $104.60M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $27.30M 10-Q · filed 2026-08-06 | $105.20M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $77.90M 10-Q · filed 2026-08-06 | |||
| 2023-09-30 | $14.90M 10-Q · filed 2023-11-08 | $88.90M derived: sum of 2 quarters · filed 2023-11-08 | $98.60M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2023-06-30 | $74.00M 10-Q · filed 2023-11-08 | $83.70M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2023-03-31 | $9.70M 10-Q · filed 2023-11-08 | |||
| 2022-09-30 | $14.90M 10-Q · filed 2022-11-07 | $24.70M derived: sum of 2 quarters · filed 2022-11-07 | $41.50M derived: sum of 3 quarters · filed 2022-11-07 | |
| 2022-06-30 | $9.80M 10-Q · filed 2022-11-07 | $26.60M derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2022-03-31 | $16.80M 10-Q · filed 2022-11-07 | |||
| 2021-12-31 | $50.50M 10-K · filed 2023-02-27 | |||
| 2021-09-30 | $172.80M 10-Q · filed 2021-11-08 | $424.70M derived: sum of 2 quarters · filed 2021-11-08 | $738.30M derived: sum of 3 quarters · filed 2021-11-08 | |
| 2021-06-30 | $251.90M 10-Q · filed 2021-11-08 | $565.50M derived: sum of 2 quarters · filed 2021-11-08 | ||
| 2021-03-31 | $313.60M 10-Q · filed 2021-11-08 | |||
| 2020-12-31 | $50.50M 10-K · filed 2022-02-28 | |||
| 2019-12-31 | $104.60M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |